When to Treat the Prostate, the Bladder, or Both?

Slides:



Advertisements
Similar presentations
Advances in the Management of BPH
Advertisements

Case 1: George Case 1: George
MODULE 5 1/33 Case 5: Sam. MODULE 5 Case 5: Sam 2/33 Patient History  Sam is a 66 year old retired painter & construction worker.  He is distressed.
MODULE 5 1/23 Case 9: Pierre. MODULE 5 Case 9: Pierre 2/23 Patient History  Pierre is 65 years of age who has suffered with benign prostatic hyperplasia.
Lower Urinary Tract Symptoms (LUTS) in men Kamal Patel GPST2.
Volume 42, Issue 1, Pages 7-11 (July 2002)
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Pascal Rischmann  European Urology Supplements 
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Volume 68, Issue 3, Pages (September 2015)
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Management of Male OAB; Current Status in Japan
Management of Acute and Chronic Retention in Men
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Rowland Illing  European Urology Supplements 
Volume 55, Issue 2, Pages (February 2009)
Volume 63, Issue 1, Pages (January 2013)
Back to the Future: Introduction and Conclusions
Evaluation and Medical Management of Benign Prostatic Hyperplasia
Volume 52, Issue 3, Pages (September 2007)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Rowland Illing  European Urology Supplements 
Marcel J. Steggerda, Henk G. van der Poel, Luc M.F. Moonen 
Volume 56, Issue 1, Pages (July 2009)
Volume 58, Issue 3, Pages (September 2010)
Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?  Bob Djavan  European.
Volume 61, Issue 3, Pages (March 2012)
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Functional Bladder Problems
Volume 44, Issue 5, Pages (November 2003)
Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old  P. Perrin,
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Richard C. Harkaway  European Urology Supplements 
Volume 50, Issue 5, Pages (November 2006)
Tim Schneider  European Urology Supplements 
Transurethral Resection of the Prostate
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Volume 54, Issue 6, Pages (December 2008)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
The Hallmarks of BPH Progression and Risk Factors
Pharmacotherapy in Stress and Mixed Incontinence
What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.
Christian Stief  European Urology Supplements 
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
Reevaluating the Health-Related Quality of Life Impact and the Economic Burden of Urgency Urinary Incontinence  Anastasios Athanasopoulos, Salvador Arlandis.
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Martin Michel, Jean de la Rosette  European Urology Supplements 
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer  P. Mongiat-Artus, P. Teillac 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Improving Flexibility and Quality of Life for Your Patients: A Must?
The Burden of Stress Urinary Incontinence
Profile of Silodosin European Urology Supplements
Stone Disease European Urology Supplements
New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Classification of Mixed Incontinence
Volume 52, Issue 6, Pages (December 2007)
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Michael Marberger  European Urology Supplements 
Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette 
Presentation transcript:

When to Treat the Prostate, the Bladder, or Both? Osama Shahin  European Urology Supplements  Volume 7, Issue 11, Pages 690-695 (November 2008) DOI: 10.1016/j.eursup.2008.08.004 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Opinions of 382 urologists participating in a Web-based survey regarding the following case: How would you treat a man aged 70 yr presenting with complaints of daytime frequency, nocturia, urgency, and terminal dribbling? He started noticing the symptoms about 4 yr ago, but they had worsened considerably in the last year. Symptom score evaluation shows that the patient has a total International Prostate Symptom Score (IPSS) of 28 with a high bother score (IPSS quality of life: 5). Additional examinations show that he has a prostate volume of 80ml, a maximum urinary flow rate (Qmax) of 9ml/s, postvoid residual of 50ml, and a prostate-specific antigen (PSA) level of 2.2ng/ml. He has a history of hypertension and is being treated with an angiotensin-converting enzyme (ACE) inhibitor. α1-AR=α1-adrenoceptor; 5-ARI=5α-reductase inhibitor. European Urology Supplements 2008 7, 690-695DOI: (10.1016/j.eursup.2008.08.004) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Opinions of 382 urologists participating in a Web-based survey regarding the following case: How would you treat a man aged 67 yr presenting to your office with the complaint that he has very bothersome lower urinary tract symptoms (urgency, frequency, nocturia, and weak stream) for more than 6 mo? International Prostate Symptom Score (IPSS) evaluation shows that he has a total IPSS of 27 and a high bother score (IPSS quality of life: 5). Further examinations show that he has a prostate volume of 29ml, a maximum urinary flow rate (Qmax) of 11ml/s, a postvoid residual of 62ml, and a prostate-specific antigen (PSA) level of 1.1 ng/ml. He is currently taking ramipril for hypertension. α1-AR=α1-adrenoceptor; 5-ARI=5α-reductase inhibitor. European Urology Supplements 2008 7, 690-695DOI: (10.1016/j.eursup.2008.08.004) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Opinions of 382 urologists participating in a Web-based survey regarding the following question: How would you treat this patient if severe storage symptoms (urgency, frequency) did not resolve after treatment with an α1-adrenoceptor antagonist? α1-AR=α1-adrenoceptor. European Urology Supplements 2008 7, 690-695DOI: (10.1016/j.eursup.2008.08.004) Copyright © 2008 European Association of Urology Terms and Conditions